To directly compare the transduction efficiencies of CD133-LV and VSVG-LV, we performed titration experiments using MOIs ranging from 0.16 to 10 in one of our primary GBM cultures, GBML3, which contains 1.7±0.1% CD133+ cells. This evidence concerns the gene PROM1 and glioblastoma.